Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"U.S. Defense Department","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMC Pharmaceuticals Awarded Sequential Phase II SBIR Grant to Continue Pharmaceutical Development of a Medical Countermeasure to Nerve Agents","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CMC Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              CMC Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CMC Pharmaceuticals Awarded Sequential Phase II SBIR Grant to Continue Pharmaceutical Development of a Medical Countermeasure to Nerve Agents

              Details:

              The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.

              Lead Product(s): Atropine Sulfate,Scopolamine

              Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: U.S. Defense Department

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding December 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY